Dearborn Partners LLC Decreases Position in Gilead Sciences, Inc. (GILD)

Dearborn Partners LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 197,828 shares of the biopharmaceutical company’s stock after selling 7,078 shares during the quarter. Dearborn Partners LLC’s holdings in Gilead Sciences were worth $14,172,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in GILD. Provident Investment Management Inc. boosted its position in shares of Gilead Sciences by 3.5% in the 2nd quarter. Provident Investment Management Inc. now owns 376,731 shares of the biopharmaceutical company’s stock valued at $26,665,000 after purchasing an additional 12,682 shares during the period. Shoker Investment Counsel Inc. boosted its position in shares of Gilead Sciences by 7.3% in the 2nd quarter. Shoker Investment Counsel Inc. now owns 4,340 shares of the biopharmaceutical company’s stock valued at $307,000 after purchasing an additional 294 shares during the period. Bienville Capital Management LLC boosted its position in shares of Gilead Sciences by 18.3% in the 2nd quarter. Bienville Capital Management LLC now owns 9,925 shares of the biopharmaceutical company’s stock valued at $702,000 after purchasing an additional 1,535 shares during the period. Freestone Capital Holdings LLC boosted its position in shares of Gilead Sciences by 2.2% in the 2nd quarter. Freestone Capital Holdings LLC now owns 282,543 shares of the biopharmaceutical company’s stock valued at $19,998,000 after purchasing an additional 6,027 shares during the period. Finally, IFM Investors Pty Ltd boosted its position in shares of Gilead Sciences by 110.6% in the 2nd quarter. IFM Investors Pty Ltd now owns 35,879 shares of the biopharmaceutical company’s stock valued at $2,540,000 after purchasing an additional 18,846 shares during the period. 77.96% of the stock is owned by institutional investors and hedge funds.

Shares of Gilead Sciences, Inc. (GILD) opened at $81.72 on Wednesday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $89.54. The company has a debt-to-equity ratio of 1.53, a quick ratio of 2.67 and a current ratio of 2.74. The firm has a market capitalization of $106,186.01, a PE ratio of 9.49, a PEG ratio of -1.86 and a beta of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. During the same period last year, the business earned $2.70 EPS. The business’s quarterly revenue was down 18.7% on a year-over-year basis. equities research analysts anticipate that Gilead Sciences, Inc. will post 6.21 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a dividend of $0.57 per share. The ex-dividend date is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.79%. Gilead Sciences’s dividend payout ratio (DPR) is 59.77%.

In related news, CFO Robin L. Washington sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total value of $401,550.00. Following the transaction, the chief financial officer now directly owns 23,749 shares of the company’s stock, valued at approximately $1,907,282.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP James R. Meyers sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total value of $8,024,000.00. Following the completion of the transaction, the executive vice president now directly owns 102,715 shares in the company, valued at $8,241,851.60. The disclosure for this sale can be found here. Insiders have sold a total of 430,268 shares of company stock valued at $34,074,395 over the last ninety days. Company insiders own 1.30% of the company’s stock.

A number of equities analysts recently weighed in on the company. Barclays reiterated an “overweight” rating and issued a $95.00 price target (up previously from $90.00) on shares of Gilead Sciences in a research report on Tuesday, March 6th. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. BidaskClub downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Mizuho set a $95.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, February 5th. Finally, Leerink Swann reissued a “market perform” rating and issued a $80.00 price objective (down from $83.00) on shares of Gilead Sciences in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $88.61.

COPYRIGHT VIOLATION NOTICE: “Dearborn Partners LLC Decreases Position in Gilead Sciences, Inc. (GILD)” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/03/14/dearborn-partners-llc-decreases-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply